Search
Vilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalThe drug is not yet fully approved for this condition.[L45849] … [L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support
Categories: Experimental Unapproved Treatments for COVID-19Esculin
go.drugbank.com/drugs/DB13155ApprovedThese are carbohydrate derivatives in which a sugar group is bonded through its anmoeric carbonA to another group via a C-, S-,N-,O-, or Se- glycosidic bond.
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnor second-line threapies for treatment-naïve patients as adjunct to sofosbuvir treatment for genotype 1 or PEG-Interferon/ribavirin combination therapy for genotype 1 or 4. … Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified as a second generation protease inhibitor.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UsePhenytoin
go.drugbank.com/drugs/DB00252ApprovedInvestigationalVet approved[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications … Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or
Cyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Categories: Antihistamines for Systemic UseColestipol
go.drugbank.com/drugs/DB00375Approvedbiliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. … [FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaMaralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients … [A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.
Dihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnThe FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]
Manganese gluconate
go.drugbank.com/drugs/DB11141ApprovedIt is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Mixtures: Multi-force for Women Tab, Multi-force for Adults TabFlavin mononucleotide
go.drugbank.com/drugs/DB03247ApprovedInvestigational[L54241] Alongside [flavin adenine dinucleotide] (FAD), for which it is a direct precursor, FMN plays critical roles in energy production, cellular function, and in the metabolism of fats, drugs, and steroids … [L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on
Mixtures: Cernevit, Lyophilisate for Reconstitution, Multivit Et Fer Ampoules Et Comprimes